Delcath Systems stock
DCTHNASDAQDelcath Systems, Inc., HealthcareISIN US24661P8077
64Score 64 out of 100, Neutral
Price and trend
78 / 100
Price history
+149% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 69% above it.
Since May 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 84).
The price is 1.8% below its 52-week high. Largest decline in 9 years: 100% (September 2018 to November 2023).
Chart figures for advanced users
- SMA 50$15.80
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$12.66
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)84
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$8.19
- The lowest closing price of the last twelve months.
- Resistance$21.77
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Delcath Systems, Inc. belongs to the Medical (Devices) industry (United States) and, with a market value of $743.77M, is number 66 of 88 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $113.07M (up 32.7%) and adjusted earnings per share of $0.05 (down 32.1%).
- MEQIRI Score 64 out of 100 (Neutral): rank 221 of 702 in Healthcare, median 53.
Show more
- The P/E is 131.8 (Medical (Devices) median 29.1, own median of recent years 126.3).
- Our model puts fair value at $13.20, with the price 62% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 120.2% a year since 2020, Medical (Devices) median 13.8%.Growth 70
- Earnings turn into cashFree cash flow 302% of earnings over the last 12 months.Fundamentals 54
- More cash than debtCash $104.32M, financial debt $2.41M.Stability 79
Weaknesses
- DilutionShare count up 1,136% since 2020.Capital allocation 45
- Volatile share priceVolatility 61% a year over the last 12 months.
Its standout strengths are momentum and stability, while capital allocation and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price up very strongly over the past year
- high price swings
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $8.80 and expensive above $26.41 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $21.69 (cash-flow model) and $4.71 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $11.30, at 7.8% it would be $16.06.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29.1).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 38.1% on the twelve months before. Revenue turned from negative at the start of the period to positive ($85.23M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 86%, operating 1%, net 3%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 25 Feb 2027in 104 days
- Last reported
- 9 Nov 2026EPS reported $0.17 (expected −$0.09)above expectations
Analyst estimates
- Earnings per share
- $0.05+126.4%
- Revenue
- $113.07M+6.2%
- Earnings per share
- $0.13+327.4%
- Revenue
- $138.2M+4.9%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook mixed
Share price after the results: +2.0%A positive adjusted EBITDA is now expected for the rest of the year, but the pace of activating new trial sites is slower.
“Forecast for 2026 gross margins remain between 85% to 87%, and we now expect to report positive adjusted EBITDA for the remainder of the year.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 7 May 2026 (fiscal Q1 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Delcath Systems
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 64
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- OrthoPediatricsKIDS $850.68M47
- MedCapMCAP.ST $825.15M74
- Varex ImagingVREX $775.81M52
- InModeINMD $759.01M70
- BioventusBVS $743.63M60
- Beta BionicsBBNX $742.78M46
- Cytek BiosciencesCTKB $721.93M46
- Synektik Spólka AkcyjnaSNT.WA $718.95M78
ETFs that hold Delcath Systems
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.02% | 0.30% | €4.28B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.02% | 0.30% | €2.22B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 10 Nov 2026, previously Weak
- Valuation signal Fairly valued since 12 Nov 2026, previously Overvalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.